Breast Cancer Update

Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, discusses recent advances in the treatment of breast cancer following the 2024 ASCO Annual Meeting.

Prof Giuseppe Curigliano from the European Institute of Oncology in Milano, Italy discusses current questions and controversies in the management of metastatic breast cancer.

Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes recent trials investigating the integration of antibody-drug conjugates for HR-positive and triple-negative metastatic breast cancer.

Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, summarizes risk factors and targeted therapy options for patients with HR-positive metastatic breast cancer.

Dr Kimberly H Allison from Stanford Cancer Institute in Stanford, California, discusses the optimal identification, pathologic reporting and treatment of HER2-low breast cancer.

Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Heather McArthur from UT Southwestern Medical Center in Dallas, Texas, summarize the evolution of biomarker-driven treatment approaches for triple-negative breast cancer.

Dr William J Gradishar from Northwestern Medicine Feinberg School of Medicine in Chicago, Illinois, Dr Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Seth Wander from Massachusetts General Hospital in Boston, discuss key findings and practical considerations with ovarian function suppression for hormone receptor-positive breast cancer.

Dr Adam M Brufsky from UPMC Hillman Cancer Center in Pittsburgh summarizes the history of and modern advances in treating localized HER2-positive breast cancers, including strategies for monitoring and managing treatment-related toxicities.

Oncology experts discuss research on metastatic triple-negative breast cancer, including a predictive survival tool and treatment approaches like immunotherapy and antibody drug conjugates. They address challenges in diagnosing and managing complications, exploring immune-related adverse events and CNS progression. The synergy of immune checkpoint inhibitors and ADCs, optimizing treatment sequencing, patient experiences with TDXD therapy, and the role of PARP inhibitors are also highlighted.

Dr Seth Wander from Harvard Medical School discusses overcoming endocrine resistance in ER-positive metastatic breast cancer. Topics include ESR1 mutations, efficacy of drugs like chamazestrant, molecular biology, precision medicine, and advancements in endocrine therapy.